Abeona Therapeutics (ABEO) investors approve equity plan boost, keep director notice rule
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Abeona Therapeutics Inc. reported results of its annual stockholder meeting held virtually on June 12, 2026. Stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors to serve until the 2029 annual meeting. They approved, on an advisory basis, the compensation of named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved increasing shares reserved for issuance under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000. A proposed amendment to remove the advance notice provision for director nominations from the certificate of incorporation received a majority of votes cast but did not obtain the required 66 2/3% of outstanding shares and therefore was not approved.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Goldan votes for: 28,305,958 votes
Zeiher votes for: 28,131,990 votes
Say-on-pay votes for: 23,300,653 votes
+4 more
7 metrics
Goldan votes for
28,305,958 votes
Election of director Keith A. Goldan
Zeiher votes for
28,131,990 votes
Election of director Bernhardt G. Zeiher, M.D.
Say-on-pay votes for
23,300,653 votes
Advisory vote on compensation of named executive officers
Auditor ratification votes for
40,560,995 votes
Ratification of Deloitte & Touche LLP as auditor for 2026
Equity plan reserve before
8,400,000 shares
Previous reserve under 2023 Equity Incentive Plan
Equity plan reserve after
11,500,000 shares
New reserve under 2023 Equity Incentive Plan
Advance notice amendment votes for
24,559,006 votes
Proposal to remove advance notice provision for director nominations
Key Terms
Broker Non-Votes, advisory vote, independent registered public accounting firm, Equity Incentive Plan, +2 more
6 terms
Broker Non-Votes financial
"Broker Non-Votes | ------------------------------------------------------------------------------- | 23,300,653"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory vote financial
"An advisory vote to approve the compensation of the Company’s named executive officers was approved"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
independent registered public accounting firm financial
"ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Equity Incentive Plan financial
"Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 8,400,000 to 11,500,000"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
advance notice provision financial
"to remove the advance notice provision for director nominations was not approved"
Amended and Restated Certificate of Incorporation financial
"amendment to the Company’s Amended and Restated Certificate of Incorporation to remove the advance notice provision"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
FAQ
What did Abeona Therapeutics (ABEO) stockholders decide at the 2026 annual meeting?
Stockholders elected two Class 1 directors, approved executive compensation on an advisory basis, ratified Deloitte & Touche LLP as auditor, and increased shares reserved under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000.
Which directors were elected to Abeona Therapeutics (ABEO) board in 2026?
Keith A. Goldan and Bernhardt G. Zeiher, M.D. were elected as Class 1 directors. They will serve until the 2029 annual meeting and hold office until their successors are elected and qualified.
Was Abeona Therapeutics (ABEO) executive compensation approved by stockholders?
Yes. Stockholders approved, on an advisory basis, the compensation of Abeona Therapeutics’ named executive officers. The advisory vote reflects stockholder views on pay but does not directly change compensation arrangements.
Did Abeona Therapeutics (ABEO) ratify its independent auditor for 2026?
Yes. Stockholders ratified the appointment of Deloitte & Touche LLP as Abeona Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with substantial support and no broker non-votes.
How did Abeona Therapeutics (ABEO) change its 2023 Equity Incentive Plan?
Stockholders approved increasing the number of shares reserved for issuance under the Second Amended and Restated 2023 Equity Incentive Plan from 8,400,000 to 11,500,000, expanding the pool available for equity-based awards.
What happened to Abeona Therapeutics (ABEO) proposal on advance notice for director nominations?
A proposal to amend the certificate of incorporation to remove the advance notice provision for director nominations received majority support but failed because it did not achieve the required 66 2/3% of outstanding common shares.